Advertisement

 

 

Type I interferon in rheumatic diseases.

Type I interferon in rheumatic diseases.
Author Information (click to view)

Muskardin TLW, Niewold TB,


Muskardin TLW, Niewold TB, (click to view)

Muskardin TLW, Niewold TB,

Advertisement

Nature reviews. Rheumatology 14(4) 214-228 doi 10.1038/nrrheum.2018.31

Abstract

The type I interferon pathway has been implicated in the pathogenesis of a number of rheumatic diseases, including systemic lupus erythematosus, Sjögren syndrome, myositis, systemic sclerosis, and rheumatoid arthritis. In normal immune responses, type I interferons have a critical role in the defence against viruses, yet in many rheumatic diseases, large subgroups of patients demonstrate persistent activation of the type I interferon pathway. Genetic variations in type I interferon-related genes are risk factors for some rheumatic diseases, and can explain some of the heterogeneity in type I interferon responses seen between patients within a given disease. Inappropriate activation of the immune response via Toll-like receptors and other nucleic acid sensors also contributes to the dysregulation of the type I interferon pathway in a number of rheumatic diseases. Theoretically, differences in type I interferon activity between patients might predict response to immune-based therapies, as has been demonstrated for rheumatoid arthritis. A number of type I interferon and type I interferon pathway blocking therapies are currently in clinical trials, the results of which are promising thus far. This Review provides an overview of the many ways in which the type I interferon system affects rheumatic diseases.

Submit a Comment

Your email address will not be published. Required fields are marked *

seven − four =

[ HIDE/SHOW ]